New drug targets Alzheimer's proteins in spinal fluid

NCT ID NCT07598370

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-stage study is testing an experimental drug called LY3439539 in 30 people with mild-to-moderate Alzheimer's disease. The main goal is to see if the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will receive the drug through an IV and have monthly visits for about 9 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3439539
What this could lead to: If successful, this could help researchers understand how LY3439539 affects Alzheimer's-related brain changes, potentially guiding future treatments.
What could go wrong: This is a very early, small Phase 1 study focused on biomarkers, not symptoms. It may not show any benefit, and the drug could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Austin Health - Heidelberg Repatriation Hospital
RECRUITING

Ivanhoe, 3079, Australia
Christchurch Neurology Trials
NOT_YET_RECRUITING

Christchurch, 8011, New Zealand
Flinders Medical Centre
NOT_YET_RECRUITING

Adelaide, 5042, Australia
Irvine Clinical Research
NOT_YET_RECRUITING

Irvine, California, 92614, United States
Lilly Centre for Clinical Pharmacology
RECRUITING

Singapore, 138623, Singapore
Macquarie University Hospital
RECRUITING

Macquarie University, 2109, Australia
Southern Neurology
RECRUITING

Kogarah, 2217, Australia
The Alfred
RECRUITING

Melbourne, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.